Friday February 24th 2017: AbbVie Inc., ABBV is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in USA, AbbVie Inc., ABBV has a market cap of 116.76 B. Since its IPO date on the 01/02/2013, AbbVie Inc., ABBV performance year to date is 16.75%. Today AbbVie Inc., ABBV has gained 0.00%, with a current price of 73.11.
Ownership of the company is 0.10% for insider ownership while institutional ownership is 70.40%. The management of the company have seen the company have a payout ratio of 60.20%. Return of assets are at 9.50%, with return on investment at 18.00%.
In terms of debt levels and profit levels, AbbVie Inc., ABBV is seeing a long-term debt/equity of 7.31. While Total debt/equity is 7.39. With a profit margin of 24.10%, this is combined with a gross margin of 76.70%, and operating margin of 36.30%. AbbVie Inc. ability to meet debt levels, with a current ratio of 1.8, while the quick ratio is 1.6.
For the last year AbbVie Inc., ABBV has seen a EPS growth of 16.20%. A performance for the year of 14.92%. The 52-week high is -0.76%, and the 52-week low is 32.78%. The average volume for AbbVie Inc., ABBV is 0.
With a target price of 74.33, can AbbVie Inc., ABBV reach this target? Looking at the value indicators of AbbVie Inc., ABBV. AbbVie Inc. has a P/E of 18.82 and a forward P/E of 11.2. Perhaps the more useful indicator than P/E, is PEG which has a value of 1.3. AbbVie Inc. also has a P/S and a P/B of 4.45 and 23.36 respectively. For P/cash, AbbVie Inc. has a value of 18.69, while it is 42.58 for P/free cash flow.
At the current price of 73.11, AbbVie Inc. has a dividend yield of 3.50%. We see a return on equity of 116.10%.
Looking more long-term AbbVie Inc., is projected to get an EPS growth for the next five years of 14.44%. In the short-term an EPS growth of 18.11% in the next year is forecasted. This is after a EPS growth of 16.20% for this year and for the last five years a 10.90% growth has been seen.